000296134 001__ 296134
000296134 005__ 20250112014723.0
000296134 0247_ $$2doi$$a10.1186/s40478-024-01921-w
000296134 0247_ $$2pmid$$apmid:39762990
000296134 0247_ $$2altmetric$$aaltmetric:172787582
000296134 037__ $$aDKFZ-2025-00064
000296134 041__ $$aEnglish
000296134 082__ $$a610
000296134 1001_ $$0P:(DE-He78)34b3639de467b2c700920d7cbc3d2110$$aOkonechnikov, Konstantin$$b0$$eFirst author$$udkfz
000296134 245__ $$aBiglycan-driven risk stratification in ZFTA-RELA fusion supratentorial ependymomas through transcriptome profiling.
000296134 260__ $$aLondon$$bBiomed Central$$c2025
000296134 3367_ $$2DRIVER$$aarticle
000296134 3367_ $$2DataCite$$aOutput Types/Journal article
000296134 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1736322199_24878
000296134 3367_ $$2BibTeX$$aARTICLE
000296134 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000296134 3367_ $$00$$2EndNote$$aJournal Article
000296134 500__ $$a#EA:B062#LA:B300#
000296134 520__ $$aRecent genomic studies have allowed the subdivision of intracranial ependymomas into molecularly distinct groups with highly specific clinical features and outcomes. The majority of supratentorial ependymomas (ST-EPN) harbor ZFTA-RELA fusions which were designated, in general, as an intermediate risk tumor variant. However, molecular prognosticators within ST-EPN ZFTA-RELA have not been determined yet. Here, we performed methylation-based DNA profiling and transcriptome RNA sequencing analysis of 80 ST-EPN ZFTA-RELA investigating the clinical significance of various molecular patterns. The principal types of ZFTA-RELA fusions, based on breakpoint location, demonstrated no significant correlations with clinical outcomes. Multigene analysis disclosed 1892 survival-associated genes, and a metagene set of 100 genes subdivided ST-EPN ZFTA-RELA into favorable and unfavorable transcriptome subtypes composed of different cell subpopulations as detected by deconvolution analysis. BGN (biglycan) was identified as the top-ranked survival-associated gene and high BGN expression levels were associated with poor survival (Hazard Ratio 17.85 for PFS and 45.48 for OS; log-rank; p-value < 0.01). Furthermore, BGN immunopositivity was identified as a strong prognostic indicator of poor survival in ST-EPN, and this finding was confirmed in an independent validation set of 56 samples. Our results indicate that integrating BGN expression (at mRNA and/or protein level) into risk stratification models may improve ST-EPN ZFTA-RELA outcome prediction. Therefore, gene and/or protein expression analyses for this molecular marker could be adopted for ST-EPN ZFTA-RELA prognostication and may help assign patients to optimal therapies in prospective clinical trials.
000296134 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000296134 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000296134 650_7 $$2Other$$aBGN
000296134 650_7 $$2Other$$aZFTA-RELA fusion
000296134 650_7 $$2Other$$aEpendymoma
000296134 650_7 $$2Other$$aExpression
000296134 650_7 $$2Other$$aPrognosis
000296134 650_7 $$2NLM Chemicals$$aTranscription Factor RelA
000296134 650_7 $$2NLM Chemicals$$aRELA protein, human
000296134 650_7 $$2NLM Chemicals$$aOncogene Proteins, Fusion
000296134 650_2 $$2MeSH$$aHumans
000296134 650_2 $$2MeSH$$aEpendymoma: genetics
000296134 650_2 $$2MeSH$$aEpendymoma: metabolism
000296134 650_2 $$2MeSH$$aEpendymoma: pathology
000296134 650_2 $$2MeSH$$aSupratentorial Neoplasms: genetics
000296134 650_2 $$2MeSH$$aSupratentorial Neoplasms: pathology
000296134 650_2 $$2MeSH$$aSupratentorial Neoplasms: metabolism
000296134 650_2 $$2MeSH$$aMale
000296134 650_2 $$2MeSH$$aFemale
000296134 650_2 $$2MeSH$$aGene Expression Profiling: methods
000296134 650_2 $$2MeSH$$aTranscription Factor RelA: genetics
000296134 650_2 $$2MeSH$$aTranscription Factor RelA: metabolism
000296134 650_2 $$2MeSH$$aAdult
000296134 650_2 $$2MeSH$$aMiddle Aged
000296134 650_2 $$2MeSH$$aAdolescent
000296134 650_2 $$2MeSH$$aChild
000296134 650_2 $$2MeSH$$aYoung Adult
000296134 650_2 $$2MeSH$$aChild, Preschool
000296134 650_2 $$2MeSH$$aAged
000296134 650_2 $$2MeSH$$aPrognosis
000296134 650_2 $$2MeSH$$aRisk Assessment: methods
000296134 650_2 $$2MeSH$$aOncogene Proteins, Fusion: genetics
000296134 650_2 $$2MeSH$$aOncogene Proteins, Fusion: metabolism
000296134 7001_ $$0P:(DE-HGF)0$$aGhasemi, David R$$b1
000296134 7001_ $$0P:(DE-He78)e54a1e0999c1d8c95869ef9188b794cc$$aSchrimpf, Daniel$$b2$$udkfz
000296134 7001_ $$aTonn, Svenja$$b3
000296134 7001_ $$aMynarek, Martin$$b4
000296134 7001_ $$aKoster, Jan$$b5
000296134 7001_ $$0P:(DE-He78)0be2f86573954f87e97f8a4dbb05cb0f$$aMilde, Till$$b6$$udkfz
000296134 7001_ $$0P:(DE-He78)1d5e6252296473fc060b71e61a22256c$$aZheng, Tuyu$$b7
000296134 7001_ $$0P:(DE-He78)8aad075b17d93a5636a34942bdbd7ee6$$aSievers, Philipp$$b8$$udkfz
000296134 7001_ $$0P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88$$aSahm, Felix$$b9$$udkfz
000296134 7001_ $$0P:(DE-He78)551bb92841f634070997aa168d818492$$aJones, David T W$$b10$$udkfz
000296134 7001_ $$0P:(DE-He78)a8a10626a848d31e70cfd96a133cc144$$avon Deimling, Andreas$$b11$$udkfz
000296134 7001_ $$0P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aPfister, Stefan M$$b12$$udkfz
000296134 7001_ $$0P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8$$aKool, Marcel$$b13$$udkfz
000296134 7001_ $$0P:(DE-He78)a7c1bbac024fa232d9c6b78443328d9d$$aPajtler, Kristian W$$b14$$udkfz
000296134 7001_ $$0P:(DE-He78)8d9c904a6cea14d4c99c78ba46e41f93$$aKorshunov, Andrey$$b15$$eLast author$$udkfz
000296134 773__ $$0PERI:(DE-600)2715589-4$$a10.1186/s40478-024-01921-w$$gVol. 13, no. 1, p. 4$$n1$$p4$$tActa Neuropathologica Communications$$v13$$x2051-5960$$y2025
000296134 909CO $$ooai:inrepo02.dkfz.de:296134$$pVDB
000296134 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)34b3639de467b2c700920d7cbc3d2110$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000296134 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000296134 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e54a1e0999c1d8c95869ef9188b794cc$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000296134 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0be2f86573954f87e97f8a4dbb05cb0f$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000296134 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)1d5e6252296473fc060b71e61a22256c$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000296134 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8aad075b17d93a5636a34942bdbd7ee6$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000296134 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000296134 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)551bb92841f634070997aa168d818492$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000296134 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a8a10626a848d31e70cfd96a133cc144$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000296134 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000296134 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000296134 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a7c1bbac024fa232d9c6b78443328d9d$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000296134 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8d9c904a6cea14d4c99c78ba46e41f93$$aDeutsches Krebsforschungszentrum$$b15$$kDKFZ
000296134 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000296134 9141_ $$y2025
000296134 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bACTA NEUROPATHOL COM : 2022$$d2023-10-26
000296134 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-26
000296134 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-26
000296134 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-26
000296134 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-05-02T09:09:14Z
000296134 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-05-02T09:09:14Z
000296134 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-05-02T09:09:14Z
000296134 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-26
000296134 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-26
000296134 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-26
000296134 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-26
000296134 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-26
000296134 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-26
000296134 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-10-26
000296134 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-26
000296134 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bACTA NEUROPATHOL COM : 2022$$d2023-10-26
000296134 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-10-26
000296134 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-10-26
000296134 9202_ $$0I:(DE-He78)B300-20160331$$kB300$$lKKE Neuropathologie$$x0
000296134 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x0
000296134 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000296134 9201_ $$0I:(DE-He78)B300-20160331$$kB300$$lKKE Neuropathologie$$x2
000296134 9201_ $$0I:(DE-He78)B310-20160331$$kB310$$lKKE Pädiatrische Onkologie$$x3
000296134 9201_ $$0I:(DE-He78)B360-20160331$$kB360$$lPädiatrische Gliomforschung$$x4
000296134 9200_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x0
000296134 980__ $$ajournal
000296134 980__ $$aVDB
000296134 980__ $$aI:(DE-He78)B062-20160331
000296134 980__ $$aI:(DE-He78)HD01-20160331
000296134 980__ $$aI:(DE-He78)B300-20160331
000296134 980__ $$aI:(DE-He78)B310-20160331
000296134 980__ $$aI:(DE-He78)B360-20160331
000296134 980__ $$aUNRESTRICTED